The funding was backed by investors including Lyva Labs and the Northern Powerhouse Investment Fund II.
"This funding allows us to take critical steps in validating and refining our technology. With the support of our partners, we are working to bring a practical solution to healthcare challenges. The collaboration between Lancaster University and Morecambe Bay NHS Foundation Trust laid the foundation for this innovation."
"The widespread success of GLP-1s for weight management has certainly changed the management landscape in obesity, but high discontinuation rates mean that they represent an imperfect solution to a complex issue. With the funding secured in this round, we will be able to significantly progress our path to clinic for DBL’s lead candidates which target greater fat vs muscle loss and provide a much-required alternative to GLP-1s for the majority of users forced to discontinue GLP-1s due to intolerance."
The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."
— Heinrich Roder, Senior Vice President of Research and Development
The funding round was backed by the Development Bank of Wales and SFC Capital.
"We want to improve the user experience so that using this technology feels as intuitive as using a smartphone. Pretty much everyone has a smartphone these days and the technology underpinning them is very sophisticated, but the end user in most cases does not need to know how that all works – it just works. PurifAI is about putting cutting-edge testing power directly into the hands of users, wherever they are and whatever their DNA question may be."